Analysts Are Pretty Bullish … NYSE:AHC, NASDAQ:XENT, NASDAQ:LUMO, NASDAQ:KDNY

A.H. BELO EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:AHC)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN A.H. BELO? (NYSE:AHC)

Wall Street analysts have given A.H. Belo a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but A.H. Belo wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.

INTERSECT ENT (NASDAQ:XENT) EARNINGS INFORMATION (NASDAQ:XENT)

Intersect ENT last issued its quarterly earnings data on March 8th, 2021. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm had revenue of $28.20 million for the quarter, compared to analysts’ expectations of $27.83 million. Its quarterly revenue was down 11.3% on a year-over-year basis. Intersect ENT has generated ($1.37) earnings per share over the last year. Intersect ENT has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, May 10th, 2021 based off prior year’s report dates.

IS INTERSECT ENT A BUY RIGHT NOW? (NASDAQ:XENT)

8 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Intersect ENT in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “hold” Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
Intersect ENT

LUMOS PHARMA (NASDAQ:LUMO) EARNINGS INFORMATION (NASDAQ:LUMO)

Lumos Pharma last announced its quarterly earnings results on March 8th, 2021. The reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.55. Lumos Pharma has generated ($9.27) earnings per share over the last year. Lumos Pharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 27th, 2021 based off prior year’s report dates.

IS LUMOS PHARMA A BUY RIGHT NOW? (NASDAQ:LUMO)

5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Lumos Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Lumos Pharma stock.
Lumos Pharma

CHINOOK THERAPEUTICS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:KDNY)

IS CHINOOK THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:KDNY)

7 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Chinook Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Chinook Therapeutics stock.
Chinook Therapeutics